DrugPatentWatch Database Preview
INFUGEM Drug Profile
When do Infugem patents expire, and when can generic versions of Infugem launch?
Infugem is a drug marketed by Sun Pharm Inds Ltd and is included in one NDA. There is one patent protecting this drug.
This drug has seventeen patent family members in fourteen countries.
The generic ingredient in INFUGEM is gemcitabine hydrochloride. There are thirty drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the gemcitabine hydrochloride profile page.
Summary for INFUGEM
| International Patents: | 17 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | INFUGEM at DailyMed |
US Patents and Regulatory Information for INFUGEM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Ltd | INFUGEM | gemcitabine hydrochloride | SOLUTION;INTRAVENOUS | 208313-001 | Jul 16, 2018 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Sun Pharm Inds Ltd | INFUGEM | gemcitabine hydrochloride | SOLUTION;INTRAVENOUS | 208313-007 | Jul 16, 2018 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Sun Pharm Inds Ltd | INFUGEM | gemcitabine hydrochloride | SOLUTION;INTRAVENOUS | 208313-004 | Jul 16, 2018 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Sun Pharm Inds Ltd | INFUGEM | gemcitabine hydrochloride | SOLUTION;INTRAVENOUS | 208313-008 | Jul 16, 2018 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Sun Pharm Inds Ltd | INFUGEM | gemcitabine hydrochloride | SOLUTION;INTRAVENOUS | 208313-002 | Jul 16, 2018 | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for INFUGEM
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2621144 | ➤ Try a Free Trial |
| Australia | 2013261012 | ➤ Try a Free Trial |
| Russian Federation | 2014147388 | ➤ Try a Free Trial |
| Japan | 6159567 | ➤ Try a Free Trial |
| European Patent Office | 2656848 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for INFUGEM
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0030 | Belgium | ➤ Try a Free Trial | PRODUCT NAME: CHLORHYDRATE DE GEMCITABINE EQUIVALENT EN GEMCITABINE; NAT. REGISTRATION NO/DATE: 58 IS 88 F 12 19960606; FIRST REGISTRATION: NL RVG 17854 19950327 |
| C/GB95/031 | United Kingdom | ➤ Try a Free Trial | PRODUCT NAME: GEMCITABINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY- ACCEPTABLE SALT; REGISTERED: NL RVG17854 19950327; UK 00006/0301 19951026; UK 00006/0302 19951026 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
